Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data

• Main Authors: David W. Dodick (Author), Anand S. Shewale (Author), Richard B. Lipton (Author), Seth J. Baum (Author), Steven C. Marcus (Author), Stephen D. Silberstein (Author), Jelena M. Pavlovic (Author), Nathan L. Bennett (Author), William B. Young (Author), Hema N. Viswanathan (Author), Jalpa A. Doshi (Author), Howard Weintraub (Author)
• Format: Book
• Published: SAGE Publishing, 2020-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors. Methods: Headache specialists, cardiologists, and health economi...